First Vioxx case goes to the jury

The defense has rested in the nation's first Vioxx trial, and the case is being turned over to a jury. According to one analyst at the trial, the odds don't look good for Merck, which had fiercely defended its handling of the Cox-2 inhibitor. A sizable award against the giant drug maker could send its stock down about 5 percent, the analyst estimated. Merck faces some 4,000 lawsuits and has set aside $675 million to defend itself. Government officials have estimated that Vioxx hurt or killed 139,000 people.

- read this report from the Boston Globe for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.